no more compounding glp 1 drugs GLP-1 from the Gray Market The GLP-1 drug shortage is
Description
This finding directly contradicts other studies showing protective effects
Ellis CE, Murphy EJ, Mitchell DC, Golovko MY, Scaglia F, Barcelo-Coblijn GC, Nussbaum RL
doi: 10.1007/s12325-022-02394-w
doi: 10.1124/pr.108.000604
This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. The Obesity Action Coalition (OAC), The Obesity Society (TOS), and The Obesity Medicine Association (OMA) have released a statement expressing their concerns for patients using the compounded GLP-1 alternatives
